Results showed that while BPC-157 excelled at localized tissue repair with 63% of participants achieving complete healing within 4 weeks, TB-500 demonstrated superior systemic benefits with 71% of subjects reporting improved overall recovery and performance metrics
Preclinical and clinical studies have demonstrated its efficacy in reducing body weight both as a monotherapy and in combination with GLP-1 receptor agonists such as semaglutide, highlighting its potential as a next-generation therapeutic agent for obesity and metabolic syndrome management
Use in Local Nasal Conditions: Utilizing nasal spray TB-500 while experiencing a local nasal condition may jeopardize systemic absorption
Animal studies have reported outcomes including reduced adiposity, improved insulin sensitivity, and altered lipid profiles, all without changes in food intake
These therapies can help reduce stress, improve immune function, enhance muscular function, drive brain body control, and promote overall physical and emotional health